Vigilant Biosciences, Inc

Vigilant Biosciences is a biotechnology company specializing in early oral cancer detection through innovative point-of-care diagnostic technologies. Founded in 2011 and based in Lakeway, Texas, the company develops the BeVigilant OraFusion System, a patented non-invasive saliva-based test that detects multiple biomarkers clinically associated with early-stage oral cancer. The system has received FDA Breakthrough Device Designation and IVDR approval for international expansion. With annual revenue of $22 million and approximately 16-22 employees, Vigilant Biosciences primarily serves dental practitioners and healthcare providers seeking to improve oral cancer detection rates and patient outcomes. The company addresses a critical clinical need, as oral cancer—the sixth most common human cancer globally—currently has 5-year survival rates below 50%, with over 70% of cases diagnosed at advanced stages. The BeVigilant OraFusion System enables chairside screening with high accuracy, transforming detection and improving survival outcomes through early intervention.